Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
Phase 1, Two-arm, Open-label Study Of Once Daily, Oral Bmn 673 In Patients With Advanced Hematological Malignancies
Sponsor: Medivation, Inc.
A PHASE1 clinical study on Acute Myeloid Leukemia and Chronic Lymphocytic Leukemia, this trial is completed. The trial is conducted by Medivation, Inc. and has accumulated 8 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE1
Status: Terminated → Completed
▶ Show 3 earlier versions
-
Sep 2017 — Oct 2017 [monthly]
Terminated PHASE1
-
Feb 2017 — Sep 2017 [monthly]
Terminated PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1
First recorded
Jun 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Medivation, Inc.
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .